Telomir Pharmaceuticals, Inc. TELO PHARMA
Company Overview
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -25.63% |
| 6 Months: | -10.53% |
| 3 Months: | -7.03% |
| 1 Month: | +2.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)54.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 38.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TELO Telomir Pharmaceuticals, Inc. PHARMA | 1.19 | -1.07 | $81.84M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 2.19M | 5.07M | 1.15M | 2.13M | 1.04M |
| Operating Income | - | - | - | - | 1.92M | - | - | - | -2.19M | -5.07M | -1.15M | -2.13M | -1.04M |
| EBITDA | - | - | - | - | - | - | - | - | -2.18M | -5.07M | -1.10M | -2.06M | -989.69K |
| Interest Expense | - | - | - | - | - | - | - | - | 46 | 1.34K | 0 | -1.39K | 1.25K |
| Pretax Income | - | - | - | - | - | - | - | - | -2.18M | -5.07M | -1.10M | -2.06M | -990.95K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -482.94K | -1.55M | -1.71M | -9.33M | -6.25M | -1.39M | -5.99M | - | -2.18M | -5.07M | -1.10M | -2.06M | -990.95K |
| Diluted EPS | -0.02 | -0.06 | -0.06 | - | -0.23 | 0.05 | -0.20 | - | -0.07 | -0.17 | -0.03 | - | -0.03 |
| R&D Expense | 440.33K | 667.63K | 262.56K | - | 804.02K | 594.80K | 627.43K | - | 337.00K | 42.84K | 759.52K | - | 467.80K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 854.15K | 3.94M | 12.24M | 10.54M |
| Operating Income | -854.15K | -3.94M | -12.24M | -10.54M |
| EBITDA | -854.15K | -11.43M | -12.19M | -10.41M |
| Interest Expense | 0 | 1.64M | 4.34M | 0 |
| Pretax Income | -854.15K | -13.07M | -16.53M | -10.41M |
| Tax Provision | - | - | - | - |
| Net Income | -854.15K | -13.07M | -16.53M | -10.41M |
| Diluted EPS | -0.03 | -0.44 | -0.56 | -0.33 |
| R&D Expense | 833.21K | 1.57M | 2.24M | 2.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 48.73K | 4.77M | 1.32M | 7.34M |
| Current Assets | - | 48.73K | 435.23K | 1.32M | 7.34M |
| Cash & Equivalents | - | 1.42K | 1.23K | 1.27M | 7.29M |
| Inventory | - | - | - | - | - |
| Receivables | - | 0 | 130.00K | 0 | - |
| Total Liabilities | - | 986.01K | 1.34M | 680.97K | 1.43M |
| Current Liabilities | - | 986.01K | 1.34M | 680.97K | 1.43M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 101.00K | - | - |
| Total Equity | - | -937.28K | 3.44M | 643.04K | 5.91M |
| Shares Outstanding | - | 29.61M | 29.61M | 29.76M | 34.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -468.66K | -3.86M | -5.07M | -3.69M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | 470.08K | 3.86M | 6.34M | 9.71M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -468.66K | -3.86M | -5.07M | -3.69M |
| Net Change in Cash | - | 1.42K | -188 | 1.26M | 6.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 91.1% | -380.2% | -2,571.0% | -176.1% |
| ROCE % | 91.1% | -114.7% | -1,903.8% | -178.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2.35% | 1.61M | $1.98M |
| 2 | Geode Capital Management, LLC | 0.49% | 338.88K | $416.82K |
| 3 | Blackrock Inc. | 0.41% | 280.47K | $344.98K |
| 4 | Vanguard Fiduciary Trust Co | 0.33% | 225.30K | $277.12K |
| 5 | State Street Corporation | 0.09% | 58.60K | $72.08K |
| 6 | Northern Trust Corporation | 0.09% | 61.53K | $75.68K |
| 7 | Bank Of New York Mellon Corporation | 0.07% | 51.45K | $63.29K |
| 8 | CAPTRUST Financial Advisors | 0.07% | 51.19K | $62.97K |
| 9 | Osaic Holdings Inc. | 0.06% | 41.49K | $51.03K |
| 10 | World Investment Advisors | 0.05% | 37.04K | $45.55K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TELO
Book value per share of Telo Genomics Corp. – HAM:3D0A - tradingview.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOM0NzSDhEdGtxenBDYlR6bVdUUnpMZmtQbWhFaDNZZW9JR0QzemFvUFFuV0QtcWxSOHFMYWkwdGFGTFhySVNhbjdqRlRJTzhBMzF1QmFwUk5ieUNlOUEwUW55MG1IUWN1Y01NWUtEMTBoNTVUeGM0eWNKSU1wdU5xZVNRR0RHZDZpVFEwNk…
Telomir Pharmaceuticals (TELO): John Paul DeJoria reports 5.169% ownership stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNbFZQeTBtOWwwbE9YaHBRR194N0E5UmxfZ2F4N0pTZkhYbVVmeEdSaU5qcFBVWi1aQndZWjlpdzhleS1meUs0cGFiQ3ZHN1BET3MyV19ZQmd4SUJGY3d1MDZZbnkxcXFEU1dvZU1xaVd4bTdNUGtGWnI5N1ZSbFJoT1FmNlp5QkVXT05zSX…
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFB0ZGJLNXE2eFc1OThxWGZJWDd1X0xnaGU1NDl6MnpXZEN4MXIxQTl2Rk4wSkJKakZuTkxnYWpMb0JZNEtUZDduQnhLbW9zb1BzaUE?oc=5" target="_blank">Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Q…
Telo Genomics Grants Stock Options - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOT2lVSWNOSlBaZzBZNzM4c0VNNEdINHA3QmtDYVIxQzBGWmMxOGJFdm5LVFo0RHlTQzh1N3VvWmw0OU9CN0diWjN3Ujh0SGRUT3pVa0dycHplQUVhbGNmLVlfN0pndEoyeXJzLWs5MkJyT0tSSXVwd3JWMjFtSFVpUFJNTzBRNUVELWR4UW…
Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPRkk4aWlNTkNLNDg0aUNNZlhwS2lrSnN6UDJ5SjN2UE1SS1Jub2NCcFQyakNqMl9LaDZ0RHhkTW9pbm9PaG9KaUg1SEJDZmtGdUQ0eWZ4NEhEWlVZRXpqTzJXSTNBWjNOUWwyT1VWcTRpNmtiTW0zLWlOUEVsa1dyN1NIZURQdVBKRm0yeH…
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNUzMwdDdrNDdEckdDcnFDMl90UVkxT3M1eU4xMHhYYTdNUUF3YXAwWC1yYzFLQXFEcTNkU29qTE1vQjFKbGYxVVU5VXdTR2htNFJwT0hBQ3VaNm5jdEI1eTNDb2JOazJpNG1mV0t6cThwVktld0M3Zi1ILWMyeEZBZ1N5R2xHU3pYLXY2YU…
TELO — Frequently Asked Questions
What is the current share price of Telomir Pharmaceuticals, Inc. (TELO)?
As of 2026-09-19 21:16 PDT, Telomir Pharmaceuticals, Inc. (TELO) trades at $1.19 on NasdaqCM. Its 52-week range is $0.92 to $1.93.
What is the market capitalisation of TELO?
Telomir Pharmaceuticals, Inc. (TELO) has a market capitalisation of $81.84M on NasdaqCM.
What is the P/E ratio of TELO?
TELO trades at a trailing price-to-earnings (P/E) ratio of -1.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.54.
Is TELO a good stock to buy?
This page provides a data-driven analysis of Telomir Pharmaceuticals, Inc. (TELO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.